Atrial Fibrillation Clinical Trials in Boston, Massachusetts

10 studies are recruiting for atrial fibrillation in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

   The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called el…

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Massachusetts General Hospital - Cardiology, Boston, Massachusetts

   Locations

   29 in total

   Run by

   Bayer

   See if you can join NCT07625215 on ClinicalTrials.gov

2. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

3. Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

   Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). This randomized control trial aims to address this unmet need by testing w…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Boston University Medical Center, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Javelin Medical

   See if you can join NCT05723926 on ClinicalTrials.gov

4. Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

   The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation …

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT06099730 on ClinicalTrials.gov

5. Assessing the Burden of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

   Background and Significance: In the United States approximately 220,000 patients undergo cardiac surgery per annum. Among potential complications, the incidence of atrial fibrillation (AF) is estimated at 30 - 60 %, and therefore presents the most common adverse event after cardiac surgery. Multipl…

   Stage

   Not phased

   Ages

   20 to 90

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT04880265 on ClinicalTrials.gov

6. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

7. Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

   * The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They a…

   Stage

   Phase 4

   Ages

   65 and older

   Site

   Boston VA CSP Coordinating Center, Boston, Massachusetts

   Locations

   5 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT06953726 on ClinicalTrials.gov

8. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov

9. Positron Emission Tomography (PET) Imaging of Thrombosis

   The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invas…

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT03830320 on ClinicalTrials.gov

10. Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

    This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.

    Stage

    Not phased

    Ages

    20 to 90

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT01258231 on ClinicalTrials.gov